FMP
NASDAQ
17.85 USD
-0.11 (-0.616%)
Dr. Kevin Koch Ph.D.
Healthcare
Biotechnology
https://www.edgewisetx.com
NASDAQ
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
0001710072
US28036F1057
28036F105
3415 Colorado Avenue
303 735 8373
US
88
Mar 26, 2021